Opinion|Videos|January 27, 2025
Ide-Cel and KarMMa-3: Exploring the latest CAR T Data for Early R/R MM
Author(s)Amrita Krishnan, MD
The panelist discusses how the KarMMa-3 trial data demonstrated the superior efficacy of ide-cel vs standard regimens in triple-class exposed R/R MM, with a median progression-free survival of 13.3 vs 4.4 months and an overall response rate of 71% vs 42%. The favorable safety profile and significant survival benefit support ide-cel as a preferred option for third-line and greater treatment, particularly in patients with good performance status who can tolerate bridging therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does the latest data from the KarMMa-3 trial inform your decision to treat with idecabtagene vicleucel (ide-cel) for early R/R MM?
- How does the efficacy and safety data impact your selection of CAR T in the 3L setting?
Advertisement
Related to this article
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.
During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.
In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
2
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
3
T-DXd Significantly Improves PFS in First-Line HER2-Mutant NSCLC
4
Amivantamab-Chemotherapy Shows Longest OS Reported in EGFR Exon 20 NSCLC
5